Production and characterization of a human antisperm monoclonal antibody against CD52g for topical contraception in women

Gabriela Baldeon-Vaca, Jai G. Marathe, Joseph A. Politch, Emilie Mausser, Jeffrey Pudney James Doud, Ellena Nador, Larry Zeitlin, Michael Pauly, Thomas R. Moench, Miles Brennan, Kevin J. Whaley, Deborah J. Anderson

Abstract

Approximately 40% of human pregnancies are unintended, indicating a need for more acceptable effective contraception methods. New antibody production systems make it possible to manufacture reagent-grade human monoclonal antibodies (mAbs) for clinical use. We used the Nicotiana platform to produce a human antisperm mAb and tested its efficacy for on-demand topical contraception.

Keywords

EpiVaginal (VEC-100-FT), human sperm, anti-sperm monoclonal antibody, human complement, contraception antibody, IgG1, VRC01-N, anti-HIV IgG1 mAb, contraception, proinflammatory cytokines, apical and basolateral cytokine secretion, IL-1RA, IL-1a, IL-1b, IL-6, IL-8, MCP-1

Materials Tested

human sperm, anti-sperm monoclonal antibody, VRC01-N, anti-HIV IgG1 monoclonal antibody

Link to Paper

Request a copy of this paper, click here.